Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Jan 16;14:1396. doi: 10.1038/s41598-023-49240-9

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2024

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

5-HT receptor antagonists can reduce COL1A1 deposition. Different 5-HT receptor antagonists were screened for their anti-fibrotic potential. Ketanserin (5-HT_2A and 5-HT_2C antagonist), pimavanserin (inverse 5-HT_2A agonist), sarpogrelate (5-HT_2A and 5-HT_2B antagonist), and SB-269970 (5-HT₇ antagonist) were added to FFA to assess their potential in decreasing COL1A1, TGF-β1, and vimentin production. Representative images of COL1A1, TGF-β1, and vimentin stainings following a 7-day treatment with FFA with or without 5-HT receptor antagonists are presented. (a) Ketanserin significantly decreased FFA-induced COL1A1, TGF-β1, and vimentin deposition (n = 4). (b) Pimavanserin decreased COL1A1, TGF-β1, and vimentin deposition, although its effect was rather variable and thus non-significant (n = 3). (c) Sarpogrelate (n = 3) and (d) SB269970 (n = 4; 1 experiment with PHH donor 1, 1 experiment with PHH donor 2, 1 experiment with PHH donor 3, and 1 experiment with PHH donor 4; NPC from donor 6 in all 4 experiments) both significantly attenuated COL1A1 deposition. Sarpogrelate also significantly reduced TGF-β1 production, whereas SB-269970 significantly reduced vimentin. Red violin plots show results of IHC analysis, where plots are created based on the fluorescence intensity (integrated density of the corresponding channel divided by the area of DAPI staining) of 10–20 sections of different spheroids per experiment. The number of experiments included in the plot is defined by n. Nuclei in the IHC images are shown in blue. The size of the spheroids is marked with a white scale bar of 100 μm. Data is shown as median with interquartile range. The width of each curve corresponds with the approximate frequency of data points in each region. Differences were tested using the student's t test.